On April 23, 2024, Cytokinetics, Incorporated entered into an employment offer letter with Sung H. Lee, pursuant to which Mr. Lee has agreed to serve as the Company's Chief Financial Officer, effective as of May 8, 2024 (start date). On the Start Date, Mr. Lee will assume the duties and responsibilities of the company's principal financial officer from Robert I. Blum, the company's President and Chief Executive Officer, who has been serving as the Company's principal financial officer on an interim basis. Mr. Lee, 53, has served as the Chief Financial Officer of Vir Biotechnology Inc. since March 2023 and will be stepping down from such role effective May 3, 2024 in order to join the Company.

Previously, from February 2021 to March 2023, he served as Chief Financial Officer and Management Board member of MorphoSys AG. Prior to that, from October 2019 to February 2021, he served as the Executive Vice President and Chief Financial Officer of Sangamo Therapeutics Inc. From December 2005 to October 2019, Mr. Lee served in various roles at Gilead Sciences Inc. most recently as Senior Vice President, Financial Planning & Analysis and Investor Relations from March 2019 to October 2019. Previously, Mr. Lee served as Vice President of Financial Planning & Analysis and Investor Relations from September 2018 to February 2019, Vice President of Investor Relations from June 2016 to August 2018 and Senior Director, Investor Relations from 2013 to May 2016.

From 2010 to 2013, Mr. Lee was the Head of Europe Financial Planning & Analysis and prior to that served as the Head of Research & Development Financial Planning & Analysis from 2006 through 2010. Mr. Lee received a B.A. from the University of California, Irvine and an M.B.T. from the University of Southern California.